scholarly journals Interoceptive awareness, positive affect, and decision making in Major Depressive Disorder

2013 ◽  
Vol 151 (2) ◽  
pp. 780-785 ◽  
Author(s):  
Daniella J. Furman ◽  
Christian E. Waugh ◽  
Kalpa Bhattacharjee ◽  
Renee J. Thompson ◽  
Ian H. Gotlib
2021 ◽  
Vol 89 (9) ◽  
pp. S362
Author(s):  
Timothy McDermott ◽  
Namik Kirlic ◽  
Ryan Smith ◽  
Elisabeth Akeman ◽  
Jessica Santiago ◽  
...  

2015 ◽  
Vol 30 (1) ◽  
pp. 121-127 ◽  
Author(s):  
C. Adoue ◽  
I. Jaussent ◽  
E. Olié ◽  
S. Beziat ◽  
F. Van den Eynde ◽  
...  

AbstractObjective:Anorexia nervosa (AN) may be associated with impaired decision-making. Cognitive processes underlying this impairment remain unclear, mainly because previous assessments of this complex cognitive function were completed with a single test. Furthermore, clinical features such as mood status may impact this association. We aim to further explore the hypothesis of altered decision-making in AN.Method:Sixty-three adult women with AN and 49 female controls completed a clinical assessment and were assessed by three tasks related to decision-making [Iowa Gambling Task (IGT), Balloon Analogue Risk Task (BART), Probabilistic Reversal Learning Task (PRLT)].Results:People with AN had poorer performance on the IGT and made less risky choices on the BART, whereas performances were not different on PRLT. Notably, AN patients with a current major depressive disorder showed similar performance to those with no current major depressive disorder.Conclusion:These results tend to confirm an impaired decision making-process in people with AN and suggest that various cognitive processes such as inhibition to risk-taking or intolerance of uncertainty may underlie this condition Furthermore, these impairments seem unrelated to the potential co-occurent major depressive disorders.


2014 ◽  
Vol 2014 ◽  
pp. 1-13 ◽  
Author(s):  
Tracy L. Greer ◽  
Prabha Sunderajan ◽  
Bruce D. Grannemann ◽  
Benji T. Kurian ◽  
Madhukar H. Trivedi

Introduction. Cognitive deficits are commonly reported by patients with major depressive disorder (MDD). Duloxetine, a dual serotonin/noradrenaline reuptake inhibitor, may improve cognitive deficits in MDD. It is unclear if cognitive improvements occur independently of antidepressant effects with standard antidepressant medications.Methods. Thirty participants with MDD who endorsed cognitive deficits at screening received 12-week duloxetine treatment. Twenty-one participants completed treatment and baseline and posttreatment cognitive testing. The Cambridge Neuropsychological Test Automated Battery was used to assess the following cognitive domains: attention, visual memory, executive function/set shifting and working memory, executive function/spatial planning, decision making and response control, and verbal learning and memory.Results. Completers showed significant cognitive improvements across several domains on tasks assessing psychomotor function and mental processing speed, with additional improvements in visual and verbal learning and memory, and affective decision making and response control. Overall significance tests for executive function tasks were also significant, although individual tasks were not, perhaps due to the small sample size. Most notably, cognitive improvements were observed independently of symptom reduction on all domains except verbal learning and memory.Conclusions. Patients reporting baseline cognitive deficits achieved cognitive improvements with duloxetine treatment, most of which were independent of symptomatic improvement. This trial is registered withNCT00933439.


2021 ◽  
Author(s):  
Kia Watkins-Martin ◽  
Despina Bolanis ◽  
Stephane R. Devantoy ◽  
Marie-Helene Pennestri ◽  
Catherine Malboeuf-Hurtubise ◽  
...  

Background: While walking in nature has been shown to improve affect in adults from the community to a greater extent than walking in urban settings, it is unknown whether such findings can be generalized to individuals suffering from depression. Using a parallel group design, this randomized controlled trial examined the effects of a single walk in nature versus urban settings on negative and positive affect in adult psychiatric outpatients diagnosed with major depressive disorder (MDD). Method: Participants recruited from a psychiatric outpatient clinic for adults with MDD were randomly assigned to a nature or urban walk condition. Thirty-seven adults (mean age=49 years) completed a single 60-minute walk. Negative and positive affect were assessed using The Positive and Negative Affect Schedule or PANAS at 6 time points: before the walk, halfway during the walk, immediately post-walk, at home before bedtime, 24 hours post-walk, and 48 hours post-walk. Results: Controlling for baseline levels of affect before the walk, individuals who walked in nature experienced overall lower levels of negative affect, F(1, 35.039)=4.239, p=.047, compared to those who walked in urban settings. Positive affect did not differ across walk conditions. Limitations: The generalizability of results are limited by the small sample size and the presence of more female than male participants. Conclusions: Walking in nature might be a useful strategy to improve the affect of adults with MDD. Future research should investigate different ways to integrate the beneficial effects of nature exposure into existing treatment plans for psychiatric outpatients with MDD. Keywords: major depressive disorder (MDD); depression; nature; greenspace; affect; randomized-control trial; physical activity


PsyCh Journal ◽  
2020 ◽  
Vol 9 (2) ◽  
pp. 199-209 ◽  
Author(s):  
Yu‐ting Gu ◽  
Chen Zhou ◽  
Juan Yang ◽  
Qin Zhang ◽  
Guo‐hui Zhu ◽  
...  

Author(s):  
Masayuki Nakano ◽  
Koji Matsuo ◽  
Mami Nakashima ◽  
Toshio Matsubara ◽  
Kenichiro Harada ◽  
...  

2012 ◽  
Vol 121 (3) ◽  
pp. 553-558 ◽  
Author(s):  
Michael T. Treadway ◽  
Nicholas A. Bossaller ◽  
Richard C. Shelton ◽  
David H. Zald

Sign in / Sign up

Export Citation Format

Share Document